BRAF and cutaneous melanoma: Moreover, UM cannot benefit from target therapy tailored for cutaneous melanoma, as BRAF inhibitors, because of the absence of the target mutation[12] and, for reasons yet to be explored, response to new immunotherapies is poorer than for cutaneous melanoma[13].